T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
BioCryst Pharmaceuticals
BCRX
$2.51B
| $1.38M | ﹤0.01% |
177,392
+16,044
| +10% | +$116K |
|
1927
Dime Commercial Bancshares
DCOM
$1.81B
| $1.38M | ﹤0.01% |
45,724
+1,689
| +4% | +$48.8K |
|
1928
Innovative Industrial Properties
IIPR
$1.67B
| $1.38M | ﹤0.01% |
29,035
-160
| -0.5% | -$8.29K |
|
1929
Liberty Global Class C
LBTYK
$3.46B
| $1.38M | ﹤0.01% |
124,588
+6,080
| +5% | +$67.6K |
|
1930
MaxLinear
MXL
$6.95B
| $1.38M | ﹤0.01% |
78,934
+2,839
| +4% | +$46.2K |
|
1931
Tompkins Financial
TMP
$1.44B
| $1.38M | ﹤0.01% |
18,973
+513
| +3% | +$35.2K |
|
1932
Alkami Technology
ALKT
$2.22B
| $1.38M | ﹤0.01% |
59,565
-1,660
| -3% | -$36.6K |
|
1933
Gentherm
THRM
$1.27B
| $1.37M | ﹤0.01% |
37,778
+5,792
| +18% | +$209K |
|
|
XHR
1934
Xenia Hotels & Resorts
XHR
$1.73B
| $1.37M | ﹤0.01% |
97,098
+875
| +0.9% | +$11.9K |
|
1935
Ardelyx
ARDX
$1.01B
| $1.37M | ﹤0.01% |
234,466
+7,146
| +3% | +$39.8K |
|
1936
John B. Sanfilippo & Son
JBSS
$989M
| $1.37M | ﹤0.01% |
19,352
+2,776
| +17% | +$189K |
|
1937
MasterBrand
MBC
$1.87B
| $1.36M | ﹤0.01% |
123,466
+5,771
| +5% | +$67.6K |
|
1938
PROG Holdings
PRG
$1.64B
| $1.36M | ﹤0.01% |
46,165
+3,699
| +9% | +$110K |
|
1939
Xeris Biopharma Holdings
XERS
$1.52B
| $1.36M | ﹤0.01% |
173,463
+6,675
| +4% | +$52.5K |
|
1940
NCR Voyix
VYX
$1.17B
| $1.36M | ﹤0.01% |
133,420
+5,372
| +4% | +$58.4K |
|
1941
JetBlue
JBLU
$2.19B
| $1.36M | ﹤0.01% |
298,612
-46,341
| -13% | -$211K |
|
|
CSR
1942
Centerspace
CSR
$925M
| $1.35M | ﹤0.01% |
20,276
+1,967
| +11% | +$124K |
|
|
FFIC
1943
DELISTED
Flushing Financial
FFIC
| $1.35M | ﹤0.01% |
89,090
+2,239
| +3% | +$33.9K |
|
1944
Pacira BioSciences
PCRX
$924M
| $1.35M | ﹤0.01% |
51,982
+2,001
| +4% | +$47.6K |
|
1945
Cerence
CRNC
$391M
| $1.34M | ﹤0.01% |
125,175
+50,300
| +67% | +$553K |
|
1946
Surgery Partners
SGRY
$2.01B
| $1.34M | ﹤0.01% |
86,646
+8,149
| +10% | +$150K |
|
1947
OceanFirst Financial
OCFC
$1.85B
| $1.34M | ﹤0.01% |
74,387
+2,329
| +3% | +$43.5K |
|
1948
Spectrum Brands
SPB
$2.03B
| $1.33M | ﹤0.01% |
22,584
-107
| -0.5% | -$6.02K |
|
1949
Encore Capital Group
ECPG
$2.07B
| $1.33M | ﹤0.01% |
24,514
+611
| +3% | +$29.4K |
|
1950
Castle Biosciences
CSTL
$960M
| $1.33M | ﹤0.01% |
34,138
+1,545
| +5% | +$49.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.